<?xml version="1.0" encoding="UTF-8"?>
<p id="p0135">Low number of lymphocytes is an important sign of severity and diagnosis in COVID-19 patients [
 <xref rid="bib73" ref-type="bibr">73</xref>]. In a study with tocilizumab, 85% of the patients had low lymphocyte counts. Although in 52.6% of patients the lymphocyte counts had returned to normal after 5 days of treatment, and their C-reactive protein levels had also returned to normal. Although CT scanning showed lung turbidity in 90.5% of the patients, suggesting that it takes a long time to recover. However, in this study, there were no reports of adverse reactions and subsequent lung infections and 90.5% of patients displayed significant progress and good prognosis, together with two critical individuals. Hence, tocilizumab can be an efficient treatment for severe COVID-19, which may be due to the blocking of IL-6-related fever and inflammatory storm response [
 <xref rid="bib72" ref-type="bibr">72</xref>].
</p>
